half life of retatrutide Availability & Timeline Switching from tirzepatide to retatrutide:

Patient education about warning signs at the time of prescribing enables early recognition and appropriate response, potentially preventing progression to severe or necrotizing pancreatitis

Retatrutide is a once-weekly injectable medicine being studied for obesity and type 2 diabetes

Not necessarily

Clinical effects at the biological level At the physiological level, orforglipron enhances first-phase insulin secretion

The Future of Retatrutide Dosing Retatrutide remains in Phase III clinical trials, and final FDA-approved dosing guidelines will likely evolve as additional long-term data emerges

Dual GIP/GLP-1 Receptor Agonists Mounjaro (Tirzepatide) Mounjaro is a once-weekly injection containing tirzepatide, manufactured by Eli Lilly